352 related articles for article (PubMed ID: 19914546)
1. Molecular imaging of breast cancer.
Oude Munnink TH; Nagengast WB; Brouwers AH; Schröder CP; Hospers GA; Lub-de Hooge MN; van der Wall E; van Diest PJ; de Vries EG
Breast; 2009 Oct; 18 Suppl 3():S66-73. PubMed ID: 19914546
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
3. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
4. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions.
Mavi A; Cermik TF; Urhan M; Puskulcu H; Basu S; Yu JQ; Zhuang H; Czerniecki B; Alavi A
J Nucl Med; 2007 Aug; 48(8):1266-72. PubMed ID: 17631558
[TBL] [Abstract][Full Text] [Related]
5. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
[TBL] [Abstract][Full Text] [Related]
6. Targeted nuclear imaging of breast cancer: status of radiotracer development and clinical applications.
Kong FL; Kim EE; Yang DJ
Cancer Biother Radiopharm; 2012 Mar; 27(2):105-12. PubMed ID: 21877909
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 99mtechnetium-pertechnetate and 123iodide SPECT with FDG-PET in patients suspicious for breast cancer.
Buchmann I; Riedmüller K; Hoffner S; Mack U; Aulmann S; Haberkorn U
Cancer Biother Radiopharm; 2007 Dec; 22(6):779-89. PubMed ID: 18158769
[TBL] [Abstract][Full Text] [Related]
8. Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography.
Bénard F; Turcotte E
Breast Cancer Res; 2005; 7(4):153-62. PubMed ID: 15987467
[TBL] [Abstract][Full Text] [Related]
9. [
Lu Y; Li M; Massicano AVF; Song PN; Mansur A; Heinzman KA; Larimer BM; Lapi SE; Sorace AG
Molecules; 2021 Mar; 26(6):. PubMed ID: 33809310
[TBL] [Abstract][Full Text] [Related]
10. A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts.
Paquette M; Phoenix S; Lawson C; Guérin B; Lecomte R; Tai LH; Turcotte ÉE; Leyton JV
EJNMMI Res; 2020 Jun; 10(1):69. PubMed ID: 32592121
[TBL] [Abstract][Full Text] [Related]
11. Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients.
Kumar P; Mercer J; Doerkson C; Tonkin K; McEwan AJ
J Pharm Pharm Sci; 2007; 10(2):256s-265s. PubMed ID: 17718929
[TBL] [Abstract][Full Text] [Related]
12. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.
van Kruchten M; Glaudemans AW; de Vries EF; Beets-Tan RG; Schröder CP; Dierckx RA; de Vries EG; Hospers GA
J Nucl Med; 2012 Feb; 53(2):182-90. PubMed ID: 22241912
[TBL] [Abstract][Full Text] [Related]
13. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.
Terwisscha van Scheltinga AG; van Dam GM; Nagengast WB; Ntziachristos V; Hollema H; Herek JL; Schröder CP; Kosterink JG; Lub-de Hoog MN; de Vries EG
J Nucl Med; 2011 Nov; 52(11):1778-85. PubMed ID: 21990576
[TBL] [Abstract][Full Text] [Related]
14. The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy.
Wahl RL; Herman JM; Ford E
Semin Radiat Oncol; 2011 Apr; 21(2):88-100. PubMed ID: 21356477
[TBL] [Abstract][Full Text] [Related]
15. Application of PET Tracers in Molecular Imaging for Breast Cancer.
Boers J; de Vries EFJ; Glaudemans AWJM; Hospers GAP; Schröder CP
Curr Oncol Rep; 2020 Jul; 22(8):85. PubMed ID: 32627087
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.
Osborne JR; Port E; Gonen M; Doane A; Yeung H; Gerald W; Cook JB; Larson S
J Nucl Med; 2010 Apr; 51(4):543-50. PubMed ID: 20237034
[TBL] [Abstract][Full Text] [Related]
17. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA
Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819
[TBL] [Abstract][Full Text] [Related]
18. The 936C>T polymorphism of the gene for vascular endothelial growth factor is associated with 18F-fluorodeoxyglucose uptake.
Wolf G; Aigner RM; Schaffler G; Langsenlehner U; Renner W; Samonigg H; Yazdani-Biuki B; Krippl P
Breast Cancer Res Treat; 2004 Dec; 88(3):205-8. PubMed ID: 15609122
[TBL] [Abstract][Full Text] [Related]
19. FDG PET, PET/CT, and breast cancer imaging.
Rosen EL; Eubank WB; Mankoff DA
Radiographics; 2007 Oct; 27 Suppl 1():S215-29. PubMed ID: 18180228
[TBL] [Abstract][Full Text] [Related]
20. PET in breast cancer.
Flanagan FL; Dehdashti F; Siegel BA
Semin Nucl Med; 1998 Oct; 28(4):290-302. PubMed ID: 9800236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
